Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
1119
¥ million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales+9.3%
基準 11,983Target13,102million
Operating profit+10.8%
基準 816Target904million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
ROE19.7% (actual for the fiscal year ended March 2026) → Not disclosed
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planNet Sales 12,194 / Operating profit 1,000 / Profit attributable to owners of the parent 664 → Net Sales 11,983 / Operating profit 816 / Profit attributable to owners of the parent 501
Key initiatives
01Initiatives to secure personnel
02Home-care specialty pharmacies
03Central-kitchen model
04Expansion into new areas
05Home-care pharmacist dispatch services
06Aid Prime
07M&A support for pharmacies undergoing business succession
08Construction and operational support services for senior facilities
09Capacity to expand facilities
10Achieving profitability at the third and fourth facilities
11Beginning preparations to open the fifth and subsequent facilities
Plan assumptionsThe fiscal year ending March 2027 assumptions for the Kirari Prime business are conservative and do not include large-scale consulting projects or Region Prime projects., The dispensing management fee for home-care patients has been reduced from 28 points to 10 points, a factor expected to worsen gross margin by 1–2%.
Segment targetSegment Home-visit pharmacy business / Net Sales ¥8,960 million / Operating profit ¥699 million / Timing Fiscal year ending March 2027 outlook, Segment Kirari Prime Business / Net Sales ¥1,242 million / Operating profit ¥724 million / Timing Fiscal year ending March 2027 outlook, Segment Primary Care Home business / Net Sales ¥2,899 million / Operating profit ¥148 million / Timing Fiscal year ending March 2027 outlook, Segment Other Businesses / Net Sales ¥0 million / Operating profit ¥0 million / Timing Fiscal year ending March 2027 outlook
Non-financial targetsIndicator name Number of home-visit patients / Target value 12,000 people / Timing Fiscal year ended March 2026, Indicator name Number of Kirari Prime member stores / Target value 2,800 stores / Timing Fiscal year ended March 2026
Risks identified by the company
Reduction in dispensing management fees under the 2026 medical fee revision
Failure to obtain approval for revenue recognition from Region Prime projects
Opening costs for new facilities in the Primary Care Home business
Lower per-resident unit prices at facilities including Kumamoto Hamasen
Reason for revision or withdrawal
Recognition of approximately ¥200 million in Region Prime revenue was ultimately not approved, resulting in both revenue and profit falling short of target
| Item | Details |
|---|---|
| Plan name | Presentation Materials on Business Plans and Growth Potential |
| Progress against the plan | Annual update |
| Sales Target | ¥11,983 million → ¥13,102 million（+9.3%） |
| Operating profit target | ¥816 million → ¥904 million（+10.7%） |
| ROE target | 19.7% (actual for the fiscal year ended March 2026) → Not disclosed |
| Segment target | Segment Home-visit pharmacy business / Net Sales ¥8,960 million / Operating profit ¥699 million / Timing Fiscal year ending March 2027 outlook, Segment Kirari Prime Business / Net Sales ¥1,242 million / Operating profit ¥724 million / Timing Fiscal year ending March 2027 outlook, Segment Primary Care Home business / Net Sales ¥2,899 million / Operating profit ¥148 million / Timing Fiscal year ending March 2027 outlook, Segment Other Businesses / Net Sales ¥0 million / Operating profit ¥0 million / Timing Fiscal year ending March 2027 outlook |
| Non-financial targets | Indicator name Number of home-visit patients / Target value 12,000 people / Timing Fiscal year ended March 2026, Indicator name Number of Kirari Prime member stores / Target value 2,800 stores / Timing Fiscal year ended March 2026 |
| Plan assumptions | The fiscal year ending March 2027 assumptions for the Kirari Prime business are conservative and do not include large-scale consulting projects or Region Prime projects., The dispensing management fee for home-care patients has been reduced from 28 points to 10 points, a factor expected to worsen gross margin by 1–2%. |
| Key initiatives | Initiatives to secure personnel, Home-care specialty pharmacies, Central-kitchen model, Expansion into new areas, Home-care pharmacist dispatch services, Aid Prime, M&A support for pharmacies undergoing business succession, Construction and operational support services for senior facilities, Capacity to expand facilities, Achieving profitability at the third and fourth facilities, Beginning preparations to open the fifth and subsequent facilities |
| Results under the previous plan | Net Sales 12,194 / Operating profit 1,000 / Profit attributable to owners of the parent 664 → Net Sales 11,983 / Operating profit 816 / Profit attributable to owners of the parent 501 |
| Reason for revision or withdrawal | Recognition of approximately ¥200 million in Region Prime revenue was ultimately not approved, resulting in both revenue and profit falling short of target |
| Risks identified | Reduction in dispensing management fees under the 2026 medical fee revision, Failure to obtain approval for revenue recognition from Region Prime projects, Opening costs for new facilities in the Primary Care Home business, Lower per-resident unit prices at facilities including Kumamoto Hamasen |
| Publication date | June 2026 |
Items this document does not state (12)
Plan periodOperating profit margin targetNet income targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cites the failure to obtain approval to recognize approximately ¥200 million in revenue from the Region Prime project, for which there had been a difference of opinion with the audit firm over revenue recognition, as the reason for the shortfall in the fiscal year ended March 2026. For the fiscal year ending March 2027, the company expects earnings growth from the normalization of cost increases and operational improvements in its home-visit pharmacy business, as well as the contribution from new Primary Care Home facilities. It has adopted conservative assumptions for the Kirari Prime business that do not include large-scale projects.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.